Ernexa Therapeutics (ERNAW) Intangibles (2010 - 2022)

Ernexa Therapeutics has reported Intangibles for 13 years, with the latest figure at $6.0 million in Q1 2022.

• For the quarter ending Q1 2022, Intangibles changed 0.17% year-over-year to $6.0 million; the trailing twelve-month figure through Mar 2022 stood at $6.0 million (changed 0.17% YoY), and the FY2021 full-year result was $6.0 million, changed 0.0% from the prior year.
• Intangibles for Q1 2022 stood at $6.0 million, roughly flat from $6.0 million in the prior quarter.
• The five-year high for Intangibles was $6.0 million in Q4 2018, with the low at $1.6 million in Q1 2018.
• Historically, Intangibles has averaged $4.3 million across 5 years, with a median of $6.0 million in 2020.
• Annual changes were most pronounced in 2018 — Intangibles surged 9200.0% — and 2019, when it sank 68.08%.
• Ernexa Therapeutics' Intangibles stood at $6.0 million in 2018, then sank by 68.08% to $1.9 million in 2019, then soared by 212.79% to $6.0 million in 2020, then changed by 0.0% to $6.0 million in 2021, then increased by 0.17% to $6.0 million in 2022.
• The last three Intangibles figures came in at $6.0 million (Q1 2022), $6.0 million (Q4 2021), and $6.0 million (Q3 2021), per Business Quant data.